{"title":"西妥昔单抗治疗难治性特发性多中心Castleman病(类似igg4相关疾病)的惊人疗效","authors":"Xing Gong, Weiwei Yan, Feng Zhang, Dongdong Zhang","doi":"10.1080/1120009X.2025.2542615","DOIUrl":null,"url":null,"abstract":"<p><p>Castleman disease (CD) and immunoglobulin G4-related disease (IgG4-RD) are rare systemic immune-mediated disorders that share similar clinical manifestations and overlapping pathological features. We present a case of insidious idiopathic multicentric CD (iMCD) with elevated serum IgG4 levels, characterized by a persistent dry cough and widespread lymphadenopathy. A 38-year-old male patient exhibited persistent dry cough, generalized lymphadenopathy, and fatigue. An inguinal lymph node biopsy showed plasma cell-type MCD characteristics, such as atrophic lymphoid follicles and significant plasma cell infiltration. Immunohistochemical staining revealed positivity for IgG, CD38, and CD138, with over 50 IgG4-positive plasma cells per high-power field and an IgG4/IgG ratio of 40%, confirming the diagnosis of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of multicentric Castleman disease (iMCD-IPL). After receiving a siltuximab-based regimen followed by radiotherapy, the patient achieved a notable partial remission. We present a case illustrating the significant efficacy of siltuximab-based therapy in iMCD-IPL, resembling IgG4-related disease.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease.\",\"authors\":\"Xing Gong, Weiwei Yan, Feng Zhang, Dongdong Zhang\",\"doi\":\"10.1080/1120009X.2025.2542615\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Castleman disease (CD) and immunoglobulin G4-related disease (IgG4-RD) are rare systemic immune-mediated disorders that share similar clinical manifestations and overlapping pathological features. We present a case of insidious idiopathic multicentric CD (iMCD) with elevated serum IgG4 levels, characterized by a persistent dry cough and widespread lymphadenopathy. A 38-year-old male patient exhibited persistent dry cough, generalized lymphadenopathy, and fatigue. An inguinal lymph node biopsy showed plasma cell-type MCD characteristics, such as atrophic lymphoid follicles and significant plasma cell infiltration. Immunohistochemical staining revealed positivity for IgG, CD38, and CD138, with over 50 IgG4-positive plasma cells per high-power field and an IgG4/IgG ratio of 40%, confirming the diagnosis of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of multicentric Castleman disease (iMCD-IPL). After receiving a siltuximab-based regimen followed by radiotherapy, the patient achieved a notable partial remission. We present a case illustrating the significant efficacy of siltuximab-based therapy in iMCD-IPL, resembling IgG4-related disease.</p>\",\"PeriodicalId\":15338,\"journal\":{\"name\":\"Journal of Chemotherapy\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1120009X.2025.2542615\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2542615","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease.
Castleman disease (CD) and immunoglobulin G4-related disease (IgG4-RD) are rare systemic immune-mediated disorders that share similar clinical manifestations and overlapping pathological features. We present a case of insidious idiopathic multicentric CD (iMCD) with elevated serum IgG4 levels, characterized by a persistent dry cough and widespread lymphadenopathy. A 38-year-old male patient exhibited persistent dry cough, generalized lymphadenopathy, and fatigue. An inguinal lymph node biopsy showed plasma cell-type MCD characteristics, such as atrophic lymphoid follicles and significant plasma cell infiltration. Immunohistochemical staining revealed positivity for IgG, CD38, and CD138, with over 50 IgG4-positive plasma cells per high-power field and an IgG4/IgG ratio of 40%, confirming the diagnosis of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of multicentric Castleman disease (iMCD-IPL). After receiving a siltuximab-based regimen followed by radiotherapy, the patient achieved a notable partial remission. We present a case illustrating the significant efficacy of siltuximab-based therapy in iMCD-IPL, resembling IgG4-related disease.
期刊介绍:
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.